Evigrade

Glucosamine

AEMPS

Aminomonosaccharide; supplement / OTC product positioned as a chondroprotective agent

ATC code: M01AX05

Brand names: Move Free, Cosamin, Schiff

Updated · Methodology

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

D

Knee osteoarthritis

Not recommended

Glucosamine is heavily marketed as a «chondroprotective agent» for knee osteoarthritis, promising «cartilage restoration» and «stopping arthritis progression». Evidence is weak. The GAIT 2006 trial (NEJM) in 1583 patients with knee OA showed no superiority over placebo on the WOMAC scale. Cochrane 2005 found a small pain reduction only for glucosamine sulphate in industry-sponsored trials; independent studies show no difference. SER 2023 does not include glucosamine in core osteoarthritis recommendations – first line is paracetamol, topical NSAIDs, physical activity and weight loss; with insufficient response, short courses of systemic NSAIDs. AEMPS classifies glucosamine products as OTC with a note on limited evidence. In Spain it is registered both as medication (Xicil, Dolenio) and as a food supplement. If glucosamine is offered as the main osteoarthritis treatment, consider seeking a second opinion: time spent on ineffective therapy delays uptake of strategies that work (exercise, weight control).

ICD-10: M17 · ICD-11: FA01

How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

Endogenous substrate for the synthesis of glycosaminoglycans and proteoglycans of articular cartilage. Theoretically: oral intake raises substrate availability for chondrocytes and may stimulate cartilage matrix synthesis. In practice oral bioavailability is around 20%, and synovial fluid concentrations are 100–500 times below those used in vitro to demonstrate chondrocyte stimulation. A weak anti-inflammatory effect through NF-κB suppression is also described. Real clinical efficacy depends on the salt form (sulphate or hydrochloride) and is markedly lower than marketing claims.

Safety

Contraindications

  • Hypersensitivity to glucosamine or to shellfish (source material)
  • Phenylketonuria (formulations with aspartame)
  • Age under 18 years
  • Pregnancy and lactation (AEMPS – lack of data)

Serious adverse effects

  • Severe allergic reactions in shellfish-sensitive patients
  • Enhanced warfarin effect with INR rise (bleeding cases reported)
  • Glycaemia increase in patients with type 2 diabetes (small effect, clinical relevance debated)

Common adverse effects

  • Dyspepsia and nausea
  • Heartburn
  • Diarrhoea or constipation
  • Headache
  • Drowsiness
  • Skin rash

Pregnancy: can you take Glucosamine?

Not classified. No human pregnancy data. In Spain glucosamine is regarded as a food supplement under RD 1487/2009, without AEMPS-recognised therapeutic indications. AEMPS and AESAN advise against use during pregnancy due to lack of data. SEGO does not include glucosamine in pregnancy pain recommendations.

Breastfeeding: can you take Glucosamine?

No data. eLactancia: «possible risk, safety not confirmed». For osteoarthritis treatment in a breastfeeding mother, paracetamol (L1) and topical NSAIDs (L2) are preferred.

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Label mentions4 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

  • ModerateInsulin
    «En pacientes con tolerancia a la glucosa alterada se monitorizarán los niveles de glucosa y, cuando proceda, las necesidades de insulina antes del tratamiento y periódicamente durante el mismo.»

    AEMPS, section 4.4 · Open on CIMA

  • Moderateinsulinaclass named in the label
    «En pacientes con tolerancia a la glucosa alterada se monitorizarán los niveles de glucosa y, cuando proceda, las necesidades de insulina antes del tratamiento y periódicamente durante el mismo.»

    AEMPS, section 4.4 · Open on CIMA

  • anticoagulantesclass named in the label
    «Existen datos limitados sobre posibles interacciones medicamentosas con glucosamina, pero se han informado elevaciones del parámetro INR con anticoagulantes orales de la vitamina K. Por lo tanto los…»

    AEMPS, section 4.5 · Open on CIMA

  • tetraciclinasclass named in the label
    «El tratamiento simultáneo de glucosamina con tetraciclinas puede incrementar la absorción y concentraciones séricas de las tetraciclinas, pero la relevancia clínica de esta interacción es…»

    AEMPS, section 4.5 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Glucosamine used for?

Glucosamine is evaluated for the following indications with varying evidence strength: Knee osteoarthritis (evidence tier D). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Glucosamine?

Common side effects of Glucosamine (≥ 1 in 100): Dyspepsia and nausea, Heartburn, Diarrhoea or constipation, Headache, Drowsiness, Skin rash. See the Safety section for uncommon and serious reactions.

Is Glucosamine safe during pregnancy?

Not classified. No human pregnancy data. In Spain glucosamine is regarded as a food supplement under RD 1487/2009, without AEMPS-recognised therapeutic indications. AEMPS and AESAN advise against use during pregnancy due to lack of data. SEGO does not include glucosamine in pregnancy pain recommendations.

Is Glucosamine compatible with breastfeeding?

No data. eLactancia: «possible risk, safety not confirmed». For osteoarthritis treatment in a breastfeeding mother, paracetamol (L1) and topical NSAIDs (L2) are preferred.

Who should not take Glucosamine?

Glucosamine is contraindicated in: Hypersensitivity to glucosamine or to shellfish (source material); Phenylketonuria (formulations with aspartame); Age under 18 years; Pregnancy and lactation (AEMPS – lack of data). Full list in the Safety section.

Official sources

Direct links to regulator labels. Open in a new tab.

Other drugs in this group

Glucosamine + Chondroitin, Ibuprofen, Ketoprofen, Ketorolac, Meloxicam, Proteolytic enzyme complex (bromelain, papain, pancreatin, trypsin, chymotrypsin, rutoside), Celecoxib, Lornoxicam